Sara Colombetti

Global Head of Oncology Discovery Pharmacology

Roche Diagnostics

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sara Colombetti is the Global Head of Oncology Discovery Pharmacology at Roche, located in Switzerland. Her research focuses on tumor microenvironments, cancer immunotherapy, and the development of innovative therapies for pediatric oncology. Recent articles authored or co-authored by Dr. Colombetti investigate critical aspects of anti-tumor immunity and the efficacy of bispecific antibodies in cancer treatment.

Articles (7)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Michael Y. Gerner

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sara Colombetti

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity

International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

Collaborators (1)

Michael Y. Gerner

Make your next move.